ATE435219T1 - Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase - Google Patents

Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Info

Publication number
ATE435219T1
ATE435219T1 AT03722769T AT03722769T ATE435219T1 AT E435219 T1 ATE435219 T1 AT E435219T1 AT 03722769 T AT03722769 T AT 03722769T AT 03722769 T AT03722769 T AT 03722769T AT E435219 T1 ATE435219 T1 AT E435219T1
Authority
AT
Austria
Prior art keywords
sulfamides
heteroaryl substituted
gamma secretase
substituted spirocyclic
inhibit gamma
Prior art date
Application number
AT03722769T
Other languages
English (en)
Inventor
Ian James Collins
Laura Catherine Cooper
Timothy Harrison
Linda Elizabeth Keown
Andrew Madin
Mark Peter Ridgill
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209996A external-priority patent/GB0209996D0/en
Priority claimed from GB0223873A external-priority patent/GB0223873D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE435219T1 publication Critical patent/ATE435219T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03722769T 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase ATE435219T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0209996A GB0209996D0 (en) 2002-05-01 2002-05-01 Therapeutic agents
GB0223873A GB0223873D0 (en) 2002-10-14 2002-10-14 Therapeutic agents
US42460802P 2002-11-07 2002-11-07
PCT/GB2003/001763 WO2003093252A1 (en) 2002-05-01 2003-04-24 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Publications (1)

Publication Number Publication Date
ATE435219T1 true ATE435219T1 (de) 2009-07-15

Family

ID=29407321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03722769T ATE435219T1 (de) 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Country Status (7)

Country Link
US (3) US7041689B2 (de)
EP (1) EP1503998B1 (de)
AT (1) ATE435219T1 (de)
AU (1) AU2003229932B2 (de)
CA (1) CA2484159C (de)
DE (1) DE60328182D1 (de)
WO (1) WO2003093252A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138400B2 (en) * 2000-11-02 2006-11-21 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
CA2471943C (en) 2001-12-27 2011-09-20 Daiichi Pharmaceutical Co., Ltd. .beta.-amyloid protein production-secretion inhibitors
GB0209995D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003229932B2 (en) * 2002-05-01 2008-12-11 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
GB0225475D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) * 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
WO2005030731A1 (en) * 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
EP1885349B1 (de) 2005-05-19 2016-03-09 Merck Sharp & Dohme Limited Sulfamide zur Behandlung von Krebs
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
CA2669693C (en) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
AU2009266098B2 (en) 2008-06-09 2015-01-22 Ludwig-Maximilians-Universitat Munchen New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
JP5809061B2 (ja) 2008-11-24 2015-11-10 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞を産生するための経路
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
MX2012006962A (es) * 2009-12-17 2012-07-17 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
EP3330377A1 (de) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
CN103282497B (zh) 2010-08-17 2018-07-10 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
KR20180117628A (ko) 2016-01-29 2018-10-29 매사추세츠 아이 앤드 이어 인퍼머리 내이 지지 세포의 확장 및 분화 및 그의 사용 방법
WO2017200762A2 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10925872B2 (en) 2016-12-16 2021-02-23 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
JP2023507634A (ja) 2019-12-17 2023-02-24 メルク・シャープ・アンド・ドーム・エルエルシー Prmt5阻害剤
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406184A (en) * 1966-05-04 1968-10-15 Du Pont Addition compounds of norbornadienes and quadricyclenes with bis(trifluoromethyl) thioketene and their s-oxides and s-dioxides
US3715362A (en) * 1970-08-17 1973-02-06 Lilly Co Eli Tetracyclic aziridine and method for its preparation
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
ATE390404T1 (de) 1997-02-27 2008-04-15 Takeda Pharmaceutical Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
CA2404125C (en) * 2000-03-20 2011-01-25 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
US7138400B2 (en) * 2000-11-02 2006-11-21 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003229932B2 (en) * 2002-05-01 2008-12-11 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Also Published As

Publication number Publication date
CA2484159C (en) 2011-02-22
US20060173054A1 (en) 2006-08-03
US20080070895A1 (en) 2008-03-20
EP1503998A1 (de) 2005-02-09
US7282513B2 (en) 2007-10-16
US7041689B2 (en) 2006-05-09
DE60328182D1 (de) 2009-08-13
CA2484159A1 (en) 2003-11-13
US20050182109A1 (en) 2005-08-18
EP1503998B1 (de) 2009-07-01
AU2003229932A1 (en) 2003-11-17
AU2003229932B2 (en) 2008-12-11
WO2003093252A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
ATE435219T1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
DE60112055D1 (de) Inhibitoren von gamma-secretase
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
NO20070606L (no) Inhibitorer av IAP
MX2008002234A (es) Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa.
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
PE20060488A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasa
IS7325A (is) alfa-(N-súlfonamíðó)acetamíð afleiður sem beta-amýlóíð tálmar
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
ATE553077T1 (de) Peptidaseinhibitoren
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
DE602004019548D1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE452896T1 (de) C3-cyanoepothilonderivate
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties